AtriCure, Inc. (NASDAQ:ATRC) Receives Consensus Rating of “Buy” from Brokerages

Shares of AtriCure, Inc. (NASDAQ:ATRC) have earned an average rating of “Buy” from the nine analysts that are currently covering the stock, MarketBeat.com reports. Nine investment analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $51.56.

ATRC has been the subject of several recent analyst reports. Stifel Nicolaus lifted their price objective on shares of AtriCure from $36.00 to $48.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $51.00 price target on shares of AtriCure in a research note on Thursday, February 13th. Oppenheimer increased their price objective on shares of AtriCure from $36.00 to $45.00 and gave the stock an “outperform” rating in a research report on Thursday, February 13th. JPMorgan Chase & Co. raised their price objective on shares of AtriCure from $40.00 to $51.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 11th. Finally, Canaccord Genuity Group upped their target price on AtriCure from $61.00 to $66.00 and gave the company a “buy” rating in a research note on Thursday, February 13th.

AtriCure Price Performance

NASDAQ:ATRC opened at $36.25 on Friday. The firm has a market capitalization of $1.77 billion, a price-to-earnings ratio of -38.16 and a beta of 1.46. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.65 and a quick ratio of 2.62. The business has a 50 day simple moving average of $37.77 and a 200-day simple moving average of $33.00. AtriCure has a 1 year low of $18.94 and a 1 year high of $43.11.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Arcadia Investment Management Corp MI bought a new stake in AtriCure during the 3rd quarter valued at $28,000. Johnson Financial Group Inc. increased its stake in shares of AtriCure by 1,184.1% during the fourth quarter. Johnson Financial Group Inc. now owns 1,618 shares of the medical device company’s stock valued at $49,000 after buying an additional 1,492 shares during the period. Heck Capital Advisors LLC bought a new stake in shares of AtriCure in the fourth quarter valued at about $60,000. Venturi Wealth Management LLC lifted its stake in AtriCure by 1,337.6% in the fourth quarter. Venturi Wealth Management LLC now owns 2,257 shares of the medical device company’s stock worth $69,000 after acquiring an additional 2,100 shares during the period. Finally, KBC Group NV grew its holdings in AtriCure by 65.3% during the 4th quarter. KBC Group NV now owns 2,360 shares of the medical device company’s stock worth $72,000 after acquiring an additional 932 shares in the last quarter. Institutional investors own 99.11% of the company’s stock.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.